Baudax Bio (BXRX) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baudax Bio Reports First Quarter 2021 Financial Results
May 5, 2021 7:00 AM EDTANJESO® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q420
Average Sales per Account Increased 30% in Q1 compared to Q420
Richard S. Casten Strengthens Management Team in Chief Financial Officer Role
Management to Host Investor Conference Call and Webcast Today at 8:00 a.m. ET
MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ: BXRX) (the Company), a pharmaceutical company focused on developing and commercializing innovative... More
